Dana Yaacov-Garbeli - 19 Apr 2024 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role
Chief Financial Officer
Signature
/s/ Dana Yaacov-Garbeli
Issuer symbol
ENTX
Transactions as of
19 Apr 2024
Transactions value $
$0
Form type
4
Filing time
23 Apr 2024, 17:32:31 UTC
Previous filing
25 Apr 2023
Next filing
18 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTX Ordinary Shares, par value NIS 0.0000769 per share Award $0 +30.2K +53.29% $0.00 86.7K 19 Apr 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTX Stock Option (right to buy) Award $0 +130K $0.00 130K 19 Apr 2024 Ordinary Shares, par value NIS 0.0000769 per share 130K $1.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represent a grant of stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.
F2 The options vest over a three-year period with 33% of the options vesting on April 19, 2025, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.